Compare AMSC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSC | AGIO |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | AMSC | AGIO |
|---|---|---|
| Price | $34.78 | $27.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $52.00 | $36.63 |
| AVG Volume (30 Days) | ★ 1.4M | 865.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.83 | $103.08 |
| Revenue Next Year | $24.80 | $126.67 |
| P/E Ratio | $11.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.98 | $22.24 |
| 52 Week High | $70.49 | $46.00 |
| Indicator | AMSC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 47.54 |
| Support Level | $31.05 | $26.05 |
| Resistance Level | $35.50 | $28.97 |
| Average True Range (ATR) | 3.36 | 1.18 |
| MACD | 0.73 | 0.06 |
| Stochastic Oscillator | 74.20 | 48.81 |
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.